Over the years, clinical trials have advanced the treatment of breast cancer and other diseases. Our Cancer Institute takes part in large, national studies sponsored by the National Cancer Institute. As part of Penn Medicine, we are able to make many leading-edge treatment protocols available here in Lancaster County. We also collaborate with our colleagues at the Abramson Cancer Center to identify any studies taking place in Philadelphia that may be a good fit for our patients.

Bringing Patients the Latest Advances in Research

The Ann B. Barshinger Cancer Institute has a clinical research department that keeps our team apprised of the latest advances in research, including new and promising therapies that are on the horizon, and clinical trials that may benefit our patients.

Our team includes a regulatory specialist and two clinical research nurses who participate in tumor boards (multidisciplinary meetings to review active cancer cases) and work closely with the physicians to identify patients who might meet the criteria for a clinical study. The nurses also help patients navigate the process of screening for and participating in clinical trials, providing education and support, symptom management, and care coordination throughout the study.

Breast Cancer Clinical Trials

Some recent breast cancer clinical trials at the Ann B. Barshinger Cancer Institute include:

  • The PALLUS Trial, which is testing whether the drug palbociclib, taken with adjuvant endocrine therapy (after surgery, chemotherapy and/or radiation therapy), will decrease the chance of recurrence compared to endocrine therapy alone. Palbociclib has already been approved for use by patients with metastatic breast cancer, with good results. This study is for patients with early stage cancer.
  • A study involving the use of chemotherapy to prevent recurrence in patients with triple negative breast cancer. Patients with this subtype of cancer lack estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), which means they do not have the option of being treated with drugs that target these receptors. Triple negative breast cancer often responds well to chemotherapy.
  • The METAMORPH Study, which involves comprehensive genomic testing and treatment matching for patients with recurrent, metastatic breast cancer. While based at Penn Medicine’s Abramson Cancer Center, our teams arranged that portions of the study could take place here in Lancaster, to make it easier for patients in our community to participate.

Learn More

Learn more about the clinical trials being conducted at the Ann B. Barshinger Cancer Institute.

The Abramson Cancer Center explains more about their cancer clinical trials

Share This Page: